Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Common Variable Immunodeficiency | 6 | 2025 | 7 | 1.620 |
Why?
|
| Immunologic Deficiency Syndromes | 4 | 2024 | 72 | 1.080 |
Why?
|
| Immune System Diseases | 2 | 2025 | 19 | 1.060 |
Why?
|
| Hypertension, Portal | 2 | 2022 | 16 | 0.920 |
Why?
|
| Healthcare Disparities | 3 | 2025 | 359 | 0.920 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2022 | 26 | 0.750 |
Why?
|
| Health Status Disparities | 1 | 2023 | 146 | 0.740 |
Why?
|
| Vaccines | 1 | 2023 | 96 | 0.740 |
Why?
|
| Viral Vaccines | 1 | 2022 | 50 | 0.730 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 87 | 0.690 |
Why?
|
| Neoplasms | 5 | 2021 | 1361 | 0.670 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 33 | 0.630 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 313 | 0.550 |
Why?
|
| Humans | 36 | 2025 | 63309 | 0.440 |
Why?
|
| Genetic Testing | 2 | 2025 | 134 | 0.430 |
Why?
|
| Artificial Intelligence | 2 | 2025 | 178 | 0.380 |
Why?
|
| Severe Combined Immunodeficiency | 2 | 2021 | 54 | 0.340 |
Why?
|
| Drug Hypersensitivity | 2 | 2020 | 28 | 0.300 |
Why?
|
| Child | 6 | 2024 | 4531 | 0.290 |
Why?
|
| Neonatal Screening | 2 | 2025 | 98 | 0.270 |
Why?
|
| Vaccination | 3 | 2023 | 363 | 0.250 |
Why?
|
| B-Lymphocytes | 3 | 2025 | 574 | 0.250 |
Why?
|
| Socioeconomic Factors | 2 | 2025 | 777 | 0.250 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2024 | 24 | 0.230 |
Why?
|
| Delayed Diagnosis | 1 | 2025 | 47 | 0.230 |
Why?
|
| Antibodies, Viral | 2 | 2023 | 325 | 0.220 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2024 | 3 | 0.220 |
Why?
|
| Vulnerable Populations | 1 | 2025 | 90 | 0.220 |
Why?
|
| Adult | 11 | 2025 | 16794 | 0.220 |
Why?
|
| Liver Diseases | 1 | 2025 | 155 | 0.220 |
Why?
|
| Celiac Disease | 1 | 2024 | 16 | 0.210 |
Why?
|
| United States | 7 | 2025 | 7827 | 0.210 |
Why?
|
| Infant, Newborn | 2 | 2025 | 1356 | 0.210 |
Why?
|
| Colitis, Microscopic | 1 | 2023 | 2 | 0.210 |
Why?
|
| Young Adult | 8 | 2025 | 4687 | 0.210 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2023 | 46 | 0.200 |
Why?
|
| Interferon Type I | 2 | 2021 | 187 | 0.190 |
Why?
|
| T-Lymphocytes | 2 | 2025 | 1007 | 0.190 |
Why?
|
| Lymphocyte Activation | 1 | 2025 | 760 | 0.190 |
Why?
|
| Hypersensitivity | 1 | 2022 | 64 | 0.190 |
Why?
|
| Hyperplasia | 1 | 2022 | 88 | 0.190 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 74 | 0.190 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 2569 | 0.190 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2023 | 102 | 0.180 |
Why?
|
| Middle Aged | 12 | 2025 | 17558 | 0.180 |
Why?
|
| Autoimmunity | 2 | 2020 | 238 | 0.180 |
Why?
|
| Male | 15 | 2025 | 29834 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 47 | 0.170 |
Why?
|
| Germinal Center | 1 | 2020 | 40 | 0.170 |
Why?
|
| Vasculitis | 1 | 2020 | 51 | 0.170 |
Why?
|
| Immune Tolerance | 1 | 2020 | 176 | 0.160 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2020 | 113 | 0.160 |
Why?
|
| Hepatitis | 1 | 2020 | 57 | 0.160 |
Why?
|
| Prevalence | 4 | 2025 | 1378 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 124 | 0.150 |
Why?
|
| Immunotherapy | 1 | 2021 | 255 | 0.150 |
Why?
|
| Female | 14 | 2025 | 32806 | 0.150 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 266 | 0.150 |
Why?
|
| Disease Progression | 1 | 2023 | 1171 | 0.150 |
Why?
|
| Aged | 9 | 2025 | 14396 | 0.150 |
Why?
|
| Liver Cirrhosis | 1 | 2020 | 171 | 0.150 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2022 | 641 | 0.140 |
Why?
|
| Adolescent | 6 | 2024 | 6247 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 350 | 0.140 |
Why?
|
| Infant | 4 | 2024 | 1650 | 0.140 |
Why?
|
| Lidocaine | 1 | 2017 | 33 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 210 | 0.130 |
Why?
|
| Quality of Life | 1 | 2024 | 1225 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 224 | 0.130 |
Why?
|
| Anesthetics, Local | 1 | 2017 | 71 | 0.130 |
Why?
|
| Airway Management | 1 | 2017 | 57 | 0.130 |
Why?
|
| Cesarean Section | 1 | 2017 | 101 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 71 | 0.120 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 777 | 0.120 |
Why?
|
| Liver | 1 | 2020 | 852 | 0.120 |
Why?
|
| Case-Control Studies | 3 | 2024 | 1120 | 0.120 |
Why?
|
| Autoimmune Diseases | 1 | 2016 | 230 | 0.110 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1184 | 0.110 |
Why?
|
| Sweden | 2 | 2024 | 58 | 0.100 |
Why?
|
| Child, Preschool | 3 | 2024 | 1995 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2024 | 2569 | 0.090 |
Why?
|
| Immunophenotyping | 2 | 2024 | 195 | 0.090 |
Why?
|
| Biomarkers | 3 | 2021 | 1397 | 0.090 |
Why?
|
| Risk Factors | 3 | 2025 | 5345 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2025 | 868 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 674 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2025 | 6638 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 718 | 0.070 |
Why?
|
| Massachusetts | 2 | 2021 | 2076 | 0.060 |
Why?
|
| CTLA-4 Antigen | 1 | 2025 | 72 | 0.060 |
Why?
|
| CD40 Ligand | 1 | 2025 | 158 | 0.060 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2025 | 53 | 0.060 |
Why?
|
| Heterozygote | 1 | 2024 | 169 | 0.050 |
Why?
|
| Receptors, CXCR5 | 1 | 2023 | 3 | 0.050 |
Why?
|
| Immunoglobulin D | 1 | 2023 | 9 | 0.050 |
Why?
|
| Language | 1 | 2025 | 150 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2025 | 211 | 0.050 |
Why?
|
| Fibrosis | 1 | 2023 | 160 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2022 | 40 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2024 | 177 | 0.050 |
Why?
|
| Comorbidity | 1 | 2025 | 1123 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2024 | 768 | 0.050 |
Why?
|
| Length of Stay | 1 | 2025 | 811 | 0.050 |
Why?
|
| Health Status | 1 | 2024 | 435 | 0.050 |
Why?
|
| Patient Readmission | 1 | 2025 | 430 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2022 | 181 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2025 | 874 | 0.040 |
Why?
|
| Desensitization, Immunologic | 1 | 2020 | 12 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2020 | 8 | 0.040 |
Why?
|
| Cytokines | 1 | 2024 | 935 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 5449 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2025 | 684 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2022 | 248 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 459 | 0.040 |
Why?
|
| Turkey | 1 | 2020 | 14 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2020 | 40 | 0.040 |
Why?
|
| Interleukin-12 | 1 | 2020 | 128 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 2020 | 103 | 0.040 |
Why?
|
| Plasma Cells | 1 | 2020 | 53 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 564 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2020 | 182 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2025 | 1347 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 287 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2021 | 184 | 0.040 |
Why?
|
| Spleen | 1 | 2020 | 483 | 0.040 |
Why?
|
| Biopsy | 1 | 2020 | 444 | 0.040 |
Why?
|
| Inpatients | 1 | 2021 | 303 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2019 | 182 | 0.030 |
Why?
|
| Angioedema | 1 | 2017 | 10 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 614 | 0.030 |
Why?
|
| Incidence | 1 | 2021 | 1376 | 0.030 |
Why?
|
| Anaphylaxis | 1 | 2017 | 40 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1082 | 0.030 |
Why?
|
| Lung | 1 | 2022 | 946 | 0.030 |
Why?
|
| Phenotype | 1 | 2020 | 1199 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 1537 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1145 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 2674 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1747 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 672 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2025 | 3032 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 3285 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 1359 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2021 | 5660 | 0.020 |
Why?
|
| Pregnancy | 1 | 2017 | 2333 | 0.020 |
Why?
|
| Animals | 1 | 2016 | 20613 | 0.010 |
Why?
|